Newest Short Interest Filing: Could Conatus Pharmaceuticals Incorporated (NASDAQ:CNAT) Go Up After Its Newest Short Interest Report?

November 30, 2016 - By Louis Casey   ·   0 Comments

Newest Short Interest Filing: Could Conatus Pharmaceuticals Incorporated (NASDAQ:CNAT) Go Up After Its Newest Short Interest Report?

The stock of Conatus Pharmaceuticals Incorporated (NASDAQ:CNAT) registered an increase of 31.34% in short interest. CNAT’s total short interest was 744,700 shares in November as published by FINRA. Its up 31.34% from 567,000 shares, reported previously. With 197,100 shares average volume, it will take short sellers 4 days to cover their CNAT’s short positions. The short interest to Conatus Pharmaceuticals Incorporated’s float is 4.12%. The stock increased 0.54% or $0.01 on November 29, hitting $1.86. Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has declined 34.97% since April 27, 2016 and is downtrending. It has underperformed by 40.19% the S&P500.

Conatus Pharmaceuticals Inc. is a biotechnology company. The company has a market cap of $46.48 million. The Firm focuses on the development and commercialization of medicines to treat liver disease. It currently has negative earnings. The Firm operates through commercialization and development of pharmaceutical products segment.

Insitutional Activity: The institutional sentiment decreased to 1.73 in Q2 2016. Its down 0.56, from 2.29 in 2016Q1. The ratio fall, as 4 funds sold all Conatus Pharmaceuticals Inc shares owned while 3 reduced positions. 5 funds bought stakes while 11 increased positions. They now own 5.01 million shares or 0.94% more from 4.96 million shares in 2016Q1.
Blackrock Fund accumulated 0% or 47,583 shares. Morgan Stanley has 9,036 shares for 0% of their US portfolio. The New York-based D E Shaw And Com has invested 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). The New Jersey-based Jacobs Levy Equity Mgmt Inc has invested 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). Barclays Public Ltd Com has 14 shares for 0% of their US portfolio. California Employees Retirement Systems, a California-based fund reported 24,900 shares. The New York-based Jpmorgan Chase And has invested 0% in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). Fincl Advisers Ltd Llc has 0% invested in the company for 148,734 shares. Goldman Sachs Grp Incorporated accumulated 0% or 14,047 shares. Fincl Bank Of America De has invested 0% of its portfolio in Conatus Pharmaceuticals Inc (NASDAQ:CNAT). Fincl Architects last reported 0% of its portfolio in the stock. Bridgeway Mngmt Inc owns 112,500 shares or 0% of their US portfolio. Reilly Financial Ltd Liability holds 0.01% or 32,011 shares in its portfolio. Healthcor Mngmt Ltd Partnership accumulated 1.06 million shares or 0.12% of the stock. Moreover, Gru Inc One Trading Limited Partnership has 0% invested in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) for 28,134 shares.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Ratings Coverage

Out of 4 analysts covering Conatus Pharma (NASDAQ:CNAT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $15.0 is the highest target while $5 is the lowest. The $8.67 average target is 366.13% above today’s ($1.86) stock price. Conatus Pharma has been the topic of 5 analyst reports since September 22, 2015 according to StockzIntelligence Inc. As per Tuesday, September 22, the company rating was initiated by H.C. Wainwright. Stifel Nicolaus maintained Conatus Pharmaceuticals Inc (NASDAQ:CNAT) on Thursday, November 5 with “Buy” rating. The company was maintained on Wednesday, November 9 by Stifel Nicolaus. The firm has “Buy” rating given on Friday, July 1 by Roth Capital.

Another recent and important Conatus Pharmaceuticals Inc (NASDAQ:CNAT) news was published by Prnewswire.com which published an article titled: “Exalenz Bioscience Announces Collaboration with Conatus Pharmaceuticals to Use …” on August 29, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>